novo nordisk glp 1 price Slashes GLP-1 List Prices! Downsized News Novo Nordisk announced on February

doi: 10.4239/wjd.v12.i7.1042 2 GaberySSalinasCGPaulsenSJAhnfelt-RnneJAlanentaloTBaqueroAFet al

On 21 May 2026 , Lilly published the long-awaited topline results from the TRIUMPH-1 Phase 3 trial, and the data is striking: participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks , with 45.3% of patients losing 30% or more a threshold previously only achievable with bariatric surgery

Key Takeaways: Cognitive and Behavioral Benefits: GLP-1 drugs were linked to reduced risks of addiction, neurocognitive disorders like Alzheimers and dementia, and psychiatric conditions such as suicidal ideation and psychosis

While this may lead to weight loss, it can also cause: muscle loss lower energy levels slower metabolism reduced strength Body recomposition focuses on preserving muscle while encouraging fat loss

Non-targeted analysis thus enabled us to find many new candidate fasting markers